Repros Therapeutics Inc. (RPRX) Downgraded to Neutral at Laidlaw

Repros Therapeutics Inc. (NASDAQ:RPRX) was downgraded by stock analysts at Laidlaw from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday, July 21st.

Repros Therapeutics (RPRX) opened at 0.35 on Friday. The firm’s 50-day moving average is $0.42 and its 200 day moving average is $0.86. Repros Therapeutics has a 52-week low of $0.30 and a 52-week high of $2.48. The firm’s market capitalization is $9.36 million.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.08. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. The business had revenue of $0.01 million during the quarter. Equities analysts anticipate that Repros Therapeutics will post ($1.07) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at [[permalink]].

A hedge fund recently raised its stake in Repros Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 1.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 727,113 shares of the biotechnology company’s stock after buying an additional 10,700 shares during the period. Renaissance Technologies LLC owned about 2.73% of Repros Therapeutics worth $873,000 at the end of the most recent quarter. 17.11% of the stock is currently owned by hedge funds and other institutional investors.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.